• 1
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003; 326: 14239.
  • 2
    Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17: 354256.
  • 3
    Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 136379.
  • 4
    Chapman MJ, Paplaud PM, Luc G et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988; 29: 44258.
  • 5
    Teng B, Thompson GR, Sniderman AD, Forte TM, Krauss RM, Kwiterovich PO. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinaemia, normolipidaemia and familial hypercholesterolaemia. Proc Natl Acad Sci USA 1983; 80: 66626.
  • 6
    Packard CJ, Demant T, Stewart JP et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000; 41: 30518.
  • 7
    Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 44759.
  • 8
    Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003; 361: 77780.
  • 9
    Elovson J, Chatterton JE, Bell GT et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29: 146173.
  • 10
    Lamarche B, Moorjani S, Lupien PJ et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Québec Cardiovascular Study. Circulation 1996; 94: 2738.
  • 11
    St-Pierre A, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 5539.
  • 12
    Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 202633.
  • 13
    Moss AJ, Goldstein RE, Marder VJ et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 251722.
  • 14
    Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis 2004; 177: 36773.
  • 15
    Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 191823.
  • 16
    Shai I, Rimm EB, Hankinson SE et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 2004; 110: 282430.
  • 17
    Jiang R, Schulze MB, Li T et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 19917.
  • 18
    Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1) trial. Am J Cardiol 2002; 90: 8994.
  • 19
    Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 19307.
  • 20
    Sharrett AR, Ballantyne CM, Coady SA et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1 and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 110813.
  • 21
    Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998; 97: 145360.
  • 22
    Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 47784.
  • 23
    Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105: 11629.
  • 24
    van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000; 20: 240813.
  • 25
    Sniderman AD, Vu H, Cianflone K. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 1991; 89: 10916.
  • 26
    Durrington PN, Bolton CN, Hartog H. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 1978; 82: 15160.
  • 27
    Williams PT, Krauss RM, Vranizan KM, Stefanick ML, Wood PD, Lindgren FT. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. ATVB 1992; 12: 33240.
  • 28
    Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990; 83: 5967.
  • 29
    Sniderman AD, Zhang XJ, Cianflone K. Governance of the concentration of plasma LDL: a re-evaluation of the LDL receptor paradigm. Atherosclerosis 2000; 148: 21529.
  • 30
    Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am 2004; 33: 40515.
  • 31
    Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6: 3817.
  • 32
    Whitfield AJ, Barrett HR, VanBockxmeer FM, Bernett JR. Lipid disorders and mutations in the apoB gene. Clin Chem 2004; 50: 172532.
  • 33
    Durrington P. Dyslipidaemia. Lancet 2003; 362: 71731.
  • 34
    Adult Treatment Panel II - National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 301523.
  • 35
    Gotto AM, Gorry GA, Thompson JR et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation 1977; 56: 87583.
  • 36
    Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74: 112.
  • 37
    Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67: 11859.
  • 38
    Rubins HB, Robins SJ, Collins D et al. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75: 1196201.
  • 39
    Sniderman AD, Castro Cabezas M, Ribalta J et al. A proposal to redefine familial combined hyperlipidaemia – third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32: 713.
  • 40
    Veerkamp MJ, de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. A nomogram to diagnose familial combined hyperlipidemia based on results of a 5-year follow-up study. Circulation 2004; 109: 29805.
  • 41
    Castro Cabezas M, DeBruin TWA, DeValk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993; 92: 1608.
  • 42
    Meijssen S, Castro Cabezas M, Twickler TB, Jansen H, Erkelens DW. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J Lipid Res 2000; 41: 1096102.
  • 43
    Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19: A2430.
  • 44
    Nordestgaard BG, Zilversmit DB. Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences. Arteriosclerosis 1989; 9: 17683.
  • 45
    Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996; 123: 4356.
  • 46
    Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990; 31: 138798.
  • 47
    Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996; 124: 26171.
  • 48
    de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol 1991; 11: 298306.
  • 49
    Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1999; 93: 18999.
  • 50
    Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295308.
  • 51
    Festa A, D'Agostino R Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999; 19: 60510.
  • 52
    Vaisanen S, Baumstark MW, Penttila I et al. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity. Thromb Haemost 1997; 78: 14959.
  • 53
    Mykkanen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 1999; 19: 27428.
  • 54
    Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J Am Med Assoc 1996; 276: 8828.
  • 55
    Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996; 276: 87581.
  • 56
    Kamigaki AS, Siscovick D, Schwartz SM et al. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol 2001; 153: 93945.
  • 57
    Austin MA, Rodriguez BL, McKnight SG et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000; 86: 4126.
  • 58
    Lamarche B, St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Despres JP. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001; 17: 85965.
  • 59
    Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 6975.
  • 60
    Williams PT, Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003; 23: 31421.
  • 61
    Campos H, Roederer GO, Lussier-Cacan S, Davignon J, Krauss RM. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 10438.
  • 62
    Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. J Am Med Assoc 2001; 286: 146874.
  • 63
    Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis Regression Study (STARS). Metab Clin Exp 1993; 42: 14617.
  • 64
    Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project. Circulation 1996; 94: 214653.
  • 65
    Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99: 195964.
  • 66
    Griffin BA, Minihane AM, Furlonger N et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci (Colch) 1999; 97: 26976.
  • 67
    Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982; 97: 8339.
  • 68
    Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metab Clin Exp 1976; 25: 31320.
  • 69
    Durrington PN, Hunt L, Ishola M, Kane JP, Stephens WP. Serum apolipoproteins AI and B and lipoprotein in middle-aged men with and without previous myocardial infarction. Br Heart J 1986; 56: 20612.
  • 70
    Barbir M, Wile D, Trayner I, Aber VR, Thompson GR. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 1988; 60: 397403.
  • 71
    Kukita H, Hamada M, Hiwada K, Kokubu T. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis 1985; 55: 1439.
  • 72
    Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995; 75: 118995.
  • 73
    Sniderman AD, St-Pierre A, Cantin B, Dagenais GR, Depres J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 11737.
  • 74
    Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe −/− and Ldlr −/− mice. ATVB 2001; 21: 156770.
  • 75
    Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between the plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 135563.
  • 76
    Keulen ETP, Kruijshoop M, Schaper NC, Hoeks APG, de Bruin TWA. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. ATVB 2002; 22: 2838.
  • 77
    Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005; 179: 33944.
  • 78
    Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81: 26B31B.
  • 79
    Wagner AM, Perez A, Zapico E, Ordonez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003; 26: 204851.
  • 80
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J Am Med Assoc 2005; 294: 32633.
  • 81
    Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 337583.
  • 82
    Bruno G, Merletti F, Biggeri A et al. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato Study. Diabetologia 2005; in press.
  • 83
    Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108: 23126.
  • 84
    Garvey WT, Kwon S, Zheng D et al. The effects of insulin resistance and type 2 diabetes mellitus on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 45362.
  • 85
    Goff DC, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metab Clin Exp 2005; 54: 26470.
  • 86
    Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation 2004; 110: 268793.
  • 87
    Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991; 37: 167682.
  • 88
    Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994; 40: 58692.
  • 89
    Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 25269.
  • 90
    Guerin M, Lassel TS, Le Goff W, Farnier MA, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. ATVB 2000; 20: 18997.
  • 91
    Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statin after acute coronary syndromes. N Engl J Med 2004; 350: 1495504.
  • 92
    Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005; 96: 3643.
  • 93
    Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 128998.
  • 94
    Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005; 46: 205460.
  • 95
    Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 93752.
  • 96
    Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001; 285: 248697.
  • 97
    Collins-Nakai RL, Dagenais GR. The role of the cardiovascular specialist in the prevention of cardiovascular diseases – executive summary. Can J Cardiol 1999; 15: 7G16G.
  • 98
    Genest J, Frohlich J, Fodor G, McPherson R, Working group on hypercholesterolemia and other dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003; 169: 9214.
  • 99
    Leiter LA, Mahon J, Chye T et al. Macrovascular complications, dyslipidemia and hypertension. Can J Diabetes 2003; 27: S5865.
  • 100
    DeBacker G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 160110.